Eli Lilly and Company Stock Analysis:
Based on the Eli Lilly and Company stock forecast from 11 analysts, the average analyst LLY Stock Price is USD 371.00 over the next 12 months. Eli Lilly and Company’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Eli Lilly and Company is Neutral, which is based on 10 positive signals and 9 negative signals. At the last closing, LLY Stock Price was USD 296.48. LLY Stock Price has changed by -4.24% over the past week, -8.15% over the past month and +28.81% over the last year.
About Eli Lilly and Company (LLY:NYE)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.
It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma.
Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin’s lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer.
It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis.
The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance.
Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis.
The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Upgrade UBS Neutral » Buy USD 335 » USD 363 2022-09-22
Maintains Morgan Stanley Overweight USD 395 » USD 412 2022-09-07
Maintains BMO Financial Outperform USD 369 » USD 396 2022-09-06
Target Raised by Citigroup USD 285 » USD 370 2022-08-25
Target Up Cantor Fitzgerald Securities USD 360 2022-08-09
Target Up UBS Outperform USD 335 2022-07-27
Raised BMO Financial USD 369 2022-07-19
Maintains Morgan Stanley Overweight USD 369 » USD 395 2022-07-08
Maintains Barclays Overweight USD 333 » USD 355 2022-07-07
Maintains JP Morgan Overweight USD 340 » USD 355 2022-06-01
Initiated by SVB Leerink Outperform USD 341 2022-05-23
Target Raised by Mizuho Securities USD 315 » USD 356 2022-05-02
Target Raised by Morgan Stanley USD 364 » USD 369 2022-04-29
Target Raised by Wells Fargo USD 280 » USD 305 2022-04-29
Target Raised by Goldman Sachs Neutral USD 234 » USD 264 2022-04-12
Target Raised Morgan Stanley Overweight USD 265 » USD 364 2022-04-06
Target Raised by Bank of America Securities USD 300 » USD 315 2022-03-17
Initiated by Daiwa Securities Outperform USD 286 2022-03-10
Maintains Mizuho Securities Buy USD 302 » USD 293 2022-02-04
Maintains Morgan Stanley Overweight USD 272 » USD 265 2022-02-04
Maintains Morgan Stanley Overweight USD 275 » USD 272 2022-01-24
Upgraded by DZ Bank Hold » Buy USD 291 2022-01-21
Target Raised by Mizuho Securities USD 272 » USD 302 2022-01-05
Maintains Wells Fargo Equal-Weight USD 270 » USD 280 2022-01-04
Target Up Sanford Bernstein Mkt Perform USD 250 » USD 300 2022-01-03
What we like:
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior risk adjusted returns
LLY Stock Price has performed well, on a risk adjusted basis, compared to its sector peers (for a hold period of at least 12 months) and is in the top quartile.
High dividend returns
LLY Stock Price has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Dividend Growth
LLY Stock Price has shown top quartile dividend growth in the previous 5 years compared to its sector
High Gross Profit to Asset Ratio
LLY Stock Price is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What we don’t like:
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Overpriced compared to earnings
LLY Stock Price is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced compared to book value
LLY Stock Price is trading high compared to its peers median on a price to book value basis.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
LLY Stock Price is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Low Revenue Growth
LLY Stock Price has shown below median revenue growth in the previous 5 years compared to its sector.